Human truncated tau is using a different mechanism from amyloid-β to damage the blood-brain barrier

Journal of Alzheimer's Disease

Volumn 18, Issue 4, 2009, Pages 897-906

  Kovac, Andrej ^a,b   Zilkova, Monika ^a,b   Deli, Maria A ^c   Zilka, Norbert ^a,b   Novak, Michal ^a,b  

^a INSTITUTE OF NEUROIMMUNOLOGY   (Slovakia)

^b Axon Neuroscience Forschungs und Entwicklungs GmbH   (Austria)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Alzheimer's disease; Blood brain barrier; Microglia; Truncated tau protein; Tumor necrosis factor (TNF )

Indexed keywords

ADENYLATE KINASE; AMYLOID BETA PROTEIN; CYTOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BLOOD VESSEL PERFORATION; BRAIN CAPILLARY; CELL CULTURE; CYTOKINE RELEASE; CYTOTOXICITY; DEGENERATIVE DISEASE; ELECTRIC RESISTANCE; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; INFLAMMATION; MICROGLIA; MICROVASCULATURE; MONOLAYER CULTURE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; RAT; TAUOPATHY;

EID: 74949115348     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-1197     Document Type: Article

References (73)

1. Burns JM, Login IS (2002) Brain death worldwide: accepted fact but no global consensus in diagnostic criteria. Neurology 59, 470
2. Dickson DW, Farlo J, Davies P, Crystal H, Fuld P, Yen SH (1988) Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques. Am J Pathol 132, 86-101.
3. Braak H, Braak E (1997) Frequency of stages of Alzheimerrelated lesions in different age categories. Neurobiol Aging 18, 351-357.
4. McGeer PL, Rogers J, McGeer EG (1994) Neuroimmune mechanisms in Alzheimer disease pathogenesis. Alzheimer Dis Assoc Disord 8, 149-158.
5. Nov́ak M (1994) Truncated tau protein as a new marker for Alzheimer's disease. Acta Virol 38, 173-189.
6. Gomez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, Hyman BT (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 16, 4491-4500.
7. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41, 17-24. (Pubitemid 27057088)
8. Scheff SW, Price DA (2006) Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. J Alzheimers Dis 9 (3 Suppl), 101-115.
9. Iqbal K, Grundke-Iqbal I (2007) Developing pharmacological therapies for Alzheimer disease. Cell Mol Life Sci 64, 2234-2244.
10. Zilka N, Kontsekova E, Novak M (2008) Chaperone-like antibodies targeting misfolded tau protein: new vistas in the immunotherapy of neurodegenerative foldopathies. J Alzheimers Dis 15, 169-179.
11. Zlokovic BV (2008) New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Neurotherapeutics 5, 409-414.
12. BretelerMM(2000)Vascular involvement in cognitive decline and dementia Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann N Y Acad Sci 903, 457-465.
13. Grammas P, Yamada M, Zlokovic B (2002) The cerebromicrovasculature: a key player in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 4, 217-223. (Pubitemid 35006053)
14. Kalaria RN, Grahovac I (1990) Serum amyloid P immunoreactivity in hippocampal tangles, plaques and vessels: implications for leakage across the blood - brain barrier in Alzheimer's disease. Brain Res 516, 349-353.
15. Kawai M, Kalaria RN, Cras P, Siedlak SL, Velasco ME, Shelton ER, Chan HW, Greenberg BD, Perry G (1993) Degeneration of vascular muscle cells in cerebral amybid angiopathy of Alzheimer disease. Brain Res 623, 142-146.
16. Buee L, Hof PR, Bouras C, Delacourte A, Perl DP, Kortison JH, Fillit HM (1994) Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol (Berl) 87, 469-480.
17. Perlmutter LS (1994) Microvascular pathology and vascular basement membrane components in Alzheimer's disease. Mol Neurobiol 9, 33-40.
18. Kalaria RN, Hegera P (1995) Differential degeneration of the cerebral microvasculature in Alzheimer's disease. Neuroreport 6, 477-480.
19. Farkas E, DeJong GI, De Vos RA, Jansen Steur EN, Luiten PG (2000) Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease. Acta Neuropathol (Berl) 100, 395-402.
20. Akiyama H, Ikeda K, Kondo H, McGeer PL (1992) Thrombin accumulation in brains of patients with Alzheimer's disease. Neurosci Lett 146, 152-154.
21. Berzin TM, Zipser BD, Rafii MS, Kuo-Leblanc V, Yancopoulos GD, Glass DJ, Fallon JR, Stopa EG (2000) Agrin and microvascular damage in Alzheimer's disease. Neurobiol Aging 21, 349-355.
22. Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, Vitek MP, Hovanesian V, Stopa EG (2007) Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 28, 977-986.
23. Donahue JE, Berzin TM, Rafii MS, Glass DJ, Yancopoulos GD, Fallon JR, Stopa EG(1999) Agrin in Alzheimer's disease: altered solubility and abnormal distribution within microvasculature and brain parenchyma. Proc Natl Acad Sci USA 96, 6468-6472.
24. Salloway S, Gur T, Berzin T, Tavares R, Zipser B, Correia S, Hovanesian V, Fallon J, Kuo-Leblanc V, Glass D, Hulette C, Rosenberg C, Vitek M, Stopa E (2002) Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease. J Neurol Sci 203-204, 183-187.
25. Banks WA (2005) Blood-brain barrier transport of cytokines: a mechanism for neuropathology. Curr Pharm Des 11, 973-984.
26. Abbott NJ (2000) Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol 20, 131-147.
27. Petty MA, Lob EH (2002) Junctional complexes of the blood- brain barrier: permeability changes in neuroinflammation. Prog Neurobiol 68, 311-323.
28. Pardridge WM (2002) Drug and gene targeting to brain with molecular trojan horses. Nat Rev Drug Discov 1, 131-139.
29. Deli M, Abraham C, Kataoka Y, Niwa M (2005) Permeability Studies on In Vitro Blood-Brain Barrier Models: Physiology, Pathology, and Pharmacology. Cell Mol Neurobiol 25, 59-127.
30. Haseloff RF, Blasig IE, Bauer HC, Bauer H. (2005) In search of the astrocytic factor(s) modulating blood-brain barrier functions in brain capillary endothelial cells in vitro. Cell Mol Neurobiol 25, 25-39.
31. Abbott NJ, R̈onnb̈ack L, Hansson E (2006) Astrocyteendothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7, 41-53.
32. Wisniewski HM, Vorbrodt AW, Wegiel J (1997) Amyloid angiopathy and blood-brain barrier changes in Alzheimer's disease. Ann N Y Acad Sci 826, 161-172.
33. Eisenhauer PB, Johnson RJ, Wells JM, Davies TA, Fine RE (2000) Toxicity of various amyloid ? peptide species in cultured human blood-brain barrier endothelial cells: increased toxicity of Dutch-type mutant. J Neurosci Res 60, 804-810.
34. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M (1996) β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380, 108-111.
35. Blanc EM, Toborek M, Mark RJ, Hennig B, Mattson MP (1997) Amyloid β-peptide induces cell monolayer albumin permeability, impairs glucose transport, and induces apoptosis in vascular endothelial cells. J Neurochem 68, 1870-1881.
36. Suo Z, Fang C, Crawford F, Mullan M (1997) Superoxide free radical and intracellular calcium mediate Aβ (1-42) induced endothelial toxicity. Brain Res 762, 144-152.
37. Zilka N, Filipcik P, Koson P, Fialova L, Skrabana R, Zilkova M, Rolkova G, Kontsekova E, Novak M (2006) Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett 580, 3582-3588.
38. Koson P, Zilka N,Kovac A,Kovacech B, Korenova M, Filipcik P, Novak M (2008) Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load. Eur J Neurosci 28, 239-246.
39. Zilka N, Stozicka Z, Kovac A, Pilipcinec E, Bugos O, Novak M (2009) Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy. J Neuroimmunol 209, 16-25.
40. Csokova N, Skrabana R, Liebig HD, Mederlyova A, Kontsek P, Novak M (2004) Rapid purification of truncated tau proteins: model approach to purification of functionally active fragments of disordered proteins, implication for neurodegenerative diseases. Protein Expr Purif 35, 366-372.
41. Krajciova G, Skrabana R, Filipcik P, NovakM(2008) Preserving free thiols of intrinsically disordered tau protein without the use of a reducing agent. Anal Biochem 383, 343-345.
42. Veszelka S, Ṕaszt́oi M, Farkas AE, Krizbai I, Ngo TK, NiwaM, Abrah́am CS, Deli MA (2007) Pentosan polysulfate protects brain endothelial cells against bacterial lipopolysaccharideinduced damages. Neurochem Int 50, 219-228.
43. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
44. Cras P, Kawai M, Siedlak S, Perry G (1991) Microglia are associated with the extracellular neurofibrillary tangles of Alzheimer disease. Brain Res 558, 312-314.
45. Perlmutter LS, Scott SA, Barron E, Chui HC (1992) MHC class II-positive microglia in human brain: association with Alzheimer lesions. J Neurosci Res 33, 549-558.
46. Dickson DW, Sinicropi S, Yen SH, Ko LW, Mattiace LA, Bucala R, VlassaraH(1996) Glycation and microglial reaction in lesions of Alzheimer's disease. Neurobiol Aging 17, 733-743.
47. DiPatre PL, Gelman BB (1997) Microglial cell activation in aging and Alzheimer disease: partial linkage with neurofibrillary tangle burden in the hippocampus. J Neuropathol Exp Neurol 56, 143-149.
48. Oka M, Katayama S,Watanabe C, Noda K, Mao JJ, Nakamura S (1998) Argyrophilic structures stimulate glial reactions in neurofibrillary tangles and senile plaques. Neurol Res 20, 121-126.
49. Overmyer M, Helisalmi S, Soininen H, Laakso M, Riekkinen P, Alafuzoff I (1999) Reactive microglia in aging and dementia: an immunohistochemical study of postmortem human brain tissue. Acta Neuropathol 97, 383-392.
50. Sheffield LG, Marquis JG, Berman NE (2000) Regional distribution of cortical microglia parallels that of neurofibrillary tangles in Alzheimer's disease. Neurosci Lett 285, 165-168.
51. Schwab C, Steele JC, McGeer PL (1996) Neurofibrillary tangles of Guam parkinson-dementia are associated with reactive microglia and complement proteins. Brain Res 707, 196-205.
52. Ishizawa K, Dickson DW (2001) Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neuropathol Exp Neurol 60, 647-657.
53. Imamura K, Sawada M, Ozaki N, Naito H, Iwata N, Ishihara R, Takeuchi T, Shibayama H (2001) Activation mechanism of brain microglia in patients with diffuse neurofibrillary tangles with calcification: A comparison with Alzheimer disease. Alzheimer Dis Assoc Disord 15, 45-50.
54. Bellucci A,Westwood AJ, Ingram E, Casamenti F, Goedert M, Spillantini MG (2004) Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am J Pathol 165, 1643-1652
55. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, LeeVM(2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351
56. Perry VH, Anthony DC, Bolton SJ, Brown HC (1997) The blood-brain barrier and the inflammatory response. Mol Med Today 3, 335-341.
57. Lossinsky AS, Shivers RR (2004) Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Histol Histopathol 19, 535-564.
58. Engelhardt B (2006) Molecular mechanisms involved in T cell migration across the blood-brain barrier. J Neural Transm 113, 477-485.
59. Xu J, Chen S,Ku G, Ahmed SH, Xu J, Chen H, HsuCY (2001) Amyloid beta peptide-induced cerebral endothelial cell death involves mitochondrial dysfunction and caspase activation, J Cerebr Blood Flow Metab 21, 702-710.
60. Farkas IG, Czigner A, Farkas E, Dobo E, Soos K, Penke B, Endresz V, Mihaly A, (2003) Beta-amyloid peptideinduced blood-brain barrier disruption facilitates T-cell entry into the rat brain, Acta Histochem 105, 115-125.
61. Wright J, Merchant R (1994) Blood-brain barrier changes following intracerebral injection of human recombinant tumor necrosis factor-α in the rat. J Neurooncol 20, 17-25.
62. De Vries HE, Blom-Roosemalen MC, Van Oosten M, De Boer AG, Van Berkel TJ, Breimer DD,Kuiper J (1996) The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol 64, 37-43.
63. Megyeri P, Nemeth L, Pabst K, Pabst M, Deli M, Abraham C (1999) 4-(2-Aminoethyl) benzenesulfonyl fluoride attenuates tumor-necrosis-factor- α-induced blood-brain barrier opening. Eur J Pharmacol 374, 207-211.
64. Yang G, Gong C, Qin Z, Liu X, Betz A (1999) Tumor necrosis factor-α expression produces increased blood-brain barrier permeability following temporarybfocal cerebral ischemia in mice. Mol Brain Res 69, 135-143.
65. Stamatovic SM, Shakui P, Keep RF, Moore BB, Kunkel SL, Van Rooijen N, Andjelkovic AV (2005) Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability. J Cerebr Blood Flow Metab 25, 593-606.
66. Deli M, Descamps L, Dehouck M, Cecchelli R, Joo F, Abraham C, Torpier G (1995) Exposure of tumor necrosis factor-α to apical membrane of bovine brain capillary endothelial cells cocultured with astrocytes induces a delayed increase of permeability and cytoplasmic stress fiber formation. J Neurosci Res 41, 717-726.
67. Mark K, Miller D (1999) Increased permeability of primary cultured brain microvessel endothelial cell monolayers following TNF-α exposure. Life Sci 64, 1941-1953.
68. Verma S, Nakaoke R, Dohgu S, Banks WA (2006) Release of cytokines by brain endothelial cells: A polarized response to lipopolysaccharide. Brain Behav Immun 20, 449-455.
69. Wischik CM, Novak M, Edwards PC, Klug A, Tichelaar W, Crowther RA (1988) Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A 85, 4884-4888.
70. Wischik CM, Novak M, Thøgersen HC, Edwards PC, Runswick MJ, Jakes R, Walker JE, Milstein C, Roth M, Klug A (1988) Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A 85, 4506-4510.
71. Blennow K (2005) CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagn 5, 661-672.
72. Ǵomez-Ramos A, D́iaz-Herńandez M, Cuadros R, Herńandez F, Avila J (2006) Extracellular tau is toxic to neuronal cells. FEBS Lett 580, 4842-4850.
73. Frost B, Jacks RL, Diamond MI (2009) Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284, 12845-12852.